Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 10/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 0.82 |
| ▸ | MMP3 | P08254 | 2/20 | 0.82 |
| ▸ | NAT1 | P18440 | 2/20 | 0.64 |
| ▸ | MYC | P01106 | 1/20 | 0.64 |
| ▸ | MAX | P61244 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7972127 | 1.00 | ADAMTS5 (1.00) | ADAMTS5MMP13MMP3NAT1MYC | |
| SCHEMBL1248886 | 0.90 | MMP13 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL1248883 | 0.90 | MMP13 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL8308267 | 0.90 | MMP13 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL7557499 | 0.89 | ADAMTS5 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL7557495 | 0.89 | ADAMTS5 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL18103062 | 0.88 | MMP13 (0.82) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL18103023 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL8188463 | 0.85 | ADAMTS5 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B | |
| SCHEMBL7972291 | 0.85 | ADAMTS5 (1.00) | ADAMTS5MMP13MMP3NAT1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6251928-B1 | ADMINISTERING BENZYLIDENE RHODANINES WHICH ARE USEFUL AS AGENTS IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH BETA-AMYLOID PEPTIDE IN A MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0677517-A1 | Treatment of Alzheimer's disease employing inhibitors of cathepsin D | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |